Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077155 · ClinicalTrials.gov registry record · Phase 1
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00077155: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00077155 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00077155, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of EMD 121974 in treating patients with solid tumors or lymphoma. Cilengitide (EMD 121974) may stop the growth of cancer cells by stopping blood flow to the cancer
Interventions
- DRUG cilengitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2003-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077155
The ClinicalTrials.gov registry entry for NCT00077155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cilengitide is the first listed.
NCT00077155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077155 about?
NCT00077155 is a clinical study titled "Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma". This phase I trial is studying the side effects and best dose of EMD 121974 in treating patients with solid tumors or lymphoma. Cilengitide (EMD 121974) may stop the growth of cancer cells by stopping blood flow to the cancer
What is the current status of trial NCT00077155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2003-12.
What interventions are being tested in trial NCT00077155?
The interventions under investigation include: cilengitide (DRUG).
Who is sponsoring clinical trial NCT00077155?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.